Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circ …
As President Donald Trump prepares to order the dismantling of the Department of Education, the financial arm of the agency – which makes loans directly…
The scope of phase I clinical trials in oncology goes beyond the conventional safety evaluation–only objectives of these trials in other specialties. Rather, most first-in-human…
This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents.
L’Inserm est solidaire du mouvement Stand Up For Science et est solidaire de tous les scientifiques exerçant aux États-Unis, où la liberté académique est aujourd’hui…
From two of TIME’s 100 Most Influential People in AI, what you need to know about AI—and how to defend yourself against bogus AI claims…
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and…
Human infections with the H7N9 influenza virus have been eliminated in China through vaccination of poultry; however, the H7N9 virus has not yet been eradicated…
Read full-text medical journal articles from Medscape’s Skills Lab: Interpreting Clinical Research with Bishal Gyawali.
Dr Bishal Gyawali discusses the importance of the primary endpoint in phase 3 clinical trials.
Nature Medicine – An updated analysis of the DYNAMIC biomarker-driven trial, including mature survival data at 5 years, supports a ctDNA-guided approach to adjuvant chemotherapy…
